Introduction
============

In 2015, cervical cancer was predicted to account for 2.2% of all new cancers (n=3,100) and 2.6% of all cancer deaths (n=761) among Korean women \[[@b1-crt-2015-425]\]. The incidence of cervical cancer is much higher than that of other gynecologic malignancies such as endometrial cancer and ovarian cancer \[[@b2-crt-2015-425]\]. As the recent survival of cervical cancer patients has improved, quality of life (QoL), including sexuality, has become an important issue for survivors \[[@b3-crt-2015-425]\].

Reports on sexuality in Korean women have been limited \[[@b4-crt-2015-425]-[@b6-crt-2015-425]\]. For women with gynecologic cancer, survivors' QoL and sexual functioning worsened after treatment \[[@b3-crt-2015-425],[@b7-crt-2015-425]\]. Treatment for cervical cancer is composed of radiotherapy, chemotherapy, and radical surgery, and various combinations of these modalities are frequently administered. Considering these aspects, some studies have evaluated the extent of deterioration according to the type of treatment \[[@b8-crt-2015-425]\]. However, small size of the study population, heterogeneity in patient's characteristics, and use of different questionnaires among the studies hinder inferences from the results. In addition, it is necessary to measure cervical cancer survivors' sexuality using authorized questionnaire sets and to perform a comparison with that of a proper control group.

Sexual-wellbeing is an important part of cancer survivorship. Therefore, precise information on this issue, which might be affected by treatment, should be provided to cancer survivors as well as to their partners. Thus, the aim of this study was to compare QoL and sexual functioning between cervical cancer survivors and healthy women.

Materials and Methods
=====================

After obtaining approval from the Institutional Review Board (NCCNCS-13-685), the current study was conducted in the outpatient clinic of the National Cancer Center, Korea during the period between February 2013 and January 2014. To be eligible for inclusion, cervical cancer survivors had to have no evidence of disease, be 18 years of age, be able to understand Korean, and had to have engaged in sexual activity within 3 months of the study. Women who had not been diagnosed with any type of cancer in their medical records and who had engaged in sexual activity within the previous 3 months were assigned to the control group. Those who refused to participate or failed to complete the questionnaires were excluded.

Enrolled women's demographic data, including age, education, family income, marital status, and occupational status, were collected by interview and review of the medical records. Women's QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Cervical Cancer module (EORTC QLQ-CX24).

The EORTC QLQ-C30 is a 30 item, cancer-specific questionnaire for assessment of five functioning scales (physical, role, emotional, cognitive, and social functions), three symptom scales (fatigue, pain, and nausea and vomiting), a scale for global health status and overall QoL, and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) \[[@b9-crt-2015-425]\]. The scales and single-item measures are scored from 0 to 100. In the functional and global health scales, higher scores indicate better functioning or status, while higher scores on the symptom scales and for the single-items reflect more problematic symptoms.

The EORTC QLQ-CX24 is a 24 item, cervical cancer-specific questionnaire composed of three multi-item scales (symptom experience, body image, and sexual/vaginal functioning) and six single-item scales (lymphedema, peripheral neuropathy, menopausal symptoms, sexual activity, sexual worry, and sexual enjoyment) \[[@b10-crt-2015-425]\]. The scales and single-item measures are also scored from 0 to 100. In sexual activity and sexual enjoyment, higher scores indicate better functioning, however, in the other scales and single-items, higher scores reflect more problematic functioning or status.

For assessment of women's sexual functioning, the Korean version of the Female Sexual Function Index (FSFI) was also used \[[@b11-crt-2015-425]\]. This 19-item questionnaire includes six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. A higher score in each domain indicates better status.

Statistical analysis was performed using the R statistical software ver. 2.12.1 (R Foundation for Statistical Computing, Vienna, Austria; ISBN 3-900051-07-0; <http://www.Rproject.org>). Because the demographic characteristics of the cervical cancer survivors and control groups were different, the two groups were matched in age, education, family income, marital status, occupational status, and exercise using propensity score matching. Count percentage, and quartile were used for analysis of the demographic and clinical characteristics of the participants. t tests were performed for comparison of continuous variables between cervical cancer survivors and control groups.

Results
=======

Among the women who agreed to participate in the study, 135 cervical cancer survivors and 220 women in the control group provided informed consent and completed the questionnaires ([Fig. 1](#f1-crt-2015-425){ref-type="fig"}). After the propensity score matching, demographic data, including age, education, family income, marital status, occupational status, and regular exercise were not significantly different between the cervical cancer survivors and control group ([Table 1](#t1-crt-2015-425){ref-type="table"}).

The clinical characteristics of cervical cancer survivors are shown in [Table 2](#t2-crt-2015-425){ref-type="table"}. The majority of cervical cancer survivors (95.2%) were International Federation of Gynecology and Obstetrics stage I and II diseases. Squamous cell carcinoma was the most frequent histologic type (77.9%). The median interval from the diagnosis of cervical cancer to the current study was 45 months (range, 5 to 211 months). The proportions of the survivors according to the intervals between diagnosis to survey were as follows: \< 2 years, 29.8%; 2-5 years, 37.5%; and \> 5 years, 32.7%.

In terms of the treatment, radical hysterectomy was performed in 63.5% of the cervical cancer patients. Twelve point five percent of the survivors received all three treatment modalities: radical hysterectomy, radiotherapy, and chemotherapy.

The comparison of the EORTC QLQ-C30 and CX24 scores between cervical cancer survivors and control group is shown in [Table 3](#t3-crt-2015-425){ref-type="table"}. Among the scales, only scores for lymphedema (mean, 20.2 vs. 12.2; p=0.022) and body image (mean, 73.1 vs. 79.6; p=0.036) were significantly different between the two groups. When the scale of sexual/vaginal functioning in EORTC QLQ-CX24 was divided into individual questions, cervical cancer survivors reported shorter vaginal length than the control group, but without statistical significance (mean, 80.6 vs. 85.4; p=0.077). Other scale scores of the EORTC QLQ-CX24 including sexual activity (32.1 vs. 30.1, p=0.583), sexual enjoyment (40.1 vs. 37.8, p=0.537), and sexual worry (26.6 vs. 22.0, p=0.214) were similar between cervical cancer survivors and control group.

The comparison of the FSFI scores between two groups is also shown in [Table 3](#t3-crt-2015-425){ref-type="table"}. Scale scores for desire (3.0 vs. 2.9, p=0.617), arousal (3.5 vs. 3.2, p=0.232), lubrication (4.1 vs. 4.0, p=0.696), orgasm (3.9 vs. 3.7, p=0.356), satisfaction (4.0 vs. 3.9, p=0.363), and pain (4.5 vs. 4.1, p=0.214) were not significantly different between cervical cancer survivors and control group.

Discussion
==========

In the current study, lymphedema was more problematic in cervical cancer survivors compared to the control group. Sexuality, both in terms of sexual activity, sexual enjoyment, and sexual worry (EORTC QLQ-CX24), and in terms of desire, arousal, lubrication, orgasm, satisfaction, and pain (FSFI) were similar between the two groups.

Data from previously published studies on cervical cancer survivors' sexuality which used the FSFI are summarized in [Table 4](#t4-crt-2015-425){ref-type="table"} \[[@b12-crt-2015-425]-[@b17-crt-2015-425]\]. Sexual functioning deteriorated after radiotherapy, radical hysterectomy, and radical trachelectomy \[[@b14-crt-2015-425]-[@b16-crt-2015-425]\]. Older age and lower level of education were associated with more deteriorated sexual functioning of the survivors \[[@b17-crt-2015-425]\]. Importantly, impact of the type of treatment on sexuality was inconsistent among the previous studies \[[@b12-crt-2015-425], [@b14-crt-2015-425]\]. In the current study, with 45 months of median interval from the diagnosis, cervical cancer survivors showed similar total FSFI scores compared to the control group (23.0 vs. 21.9, p=0.300).

It has been reported that survivors of gynecologic malignancies express a reluctance to engage in sexual activity due to the fear of recurrence \[[@b18-crt-2015-425]\]. In the current study, the proportion of women excluded because of absence of sexual activity within 3 months was 38.2% (91/238) in cervical cancer survivors, whereas it was only 10.6% (28/265) in the control group. In addition, as Asians are known to be more sexually conservative, Korean women are considered to have relatively lower levels of sexual interest and activity \[[@b19-crt-2015-425]\]. These features might result in similar sexual functioning between cervical cancer survivors and control group.

In the current study, the target participants were limited to women who had engaged in sexual activity within 3 months. Although the diagnosis of sexual dysfunction is usually evaluated sexual problems within the last 6 months at DSM-5, the Japanese researchers who developed the Japanese version of the FSFI proposed sexual activity within 3 months \[[@b20-crt-2015-425]\]. Accordingly, women who had sexual activity within 3 months, rather than 6 months, were enrolled in this study.

The QoL of cervical cancer survivors has improved over time \[[@b21-crt-2015-425]\]. A similar level of QoL between cervical cancer survivors and control groups may be explained by the relatively long interval from the diagnosis to the survey (median, 45 months), as well as by the survivors' disease-free state.

Body image is a part of the QoL. The majority of rectal, gastric, and head and neck cancer patients have shown a deteriorated body image \[[@b22-crt-2015-425],[@b23-crt-2015-425]\]. The aggravated body image during cancer treatment may recover gradually after treatment. However, body image is often not fully recovered, even 5 years after treatment \[[@b23-crt-2015-425]\]. Body image is also known to be affected by socioeconomic status.

Interestingly, the cervical cancer survivors in the current study showed better body image than women in the control group (73.1 vs. 79.6, p=0.036). Possible reasons for this finding may be as follows. (1) Through the three concise questions for measurement of body image, quantitative or detailed measurement of body image was limited. (2) Korean women tend to be sensitive regarding their appearance and to have more body dissatisfaction. According to the previous study comparing body satisfaction across groups of college women from Korea, China, and the United States, the highest dissatisfaction was observed in Korean women \[[@b24-crt-2015-425]\]. In the Korea National Health and Nutrition Examination Survey, 2007-2010, a quarter of underweight adult Korean women (25.4%) have tried to control weight, and this attempt was influenced by distorted body image \[[@b25-crt-2015-425]\]. Therefore, even Korean women who are healthy and without disease may have poor body image. (3) Last, because of propensity score matching, socioeconomic status, known to be associated with altered body image, was not different between the two groups.

The symptoms of lymphedema were aggravated in cervical cancer survivors compared to the control group, as treatment for cervical cancer includes pelvic lymph node dissection as part of surgical treatment, chemotherapy, or radiotherapy in the pelvic area. After surgery and radiotherapy, a damaged lymphatic system is not fully recovered. The prolonged or persistent lymphedema-related symptoms have been also known to cause deterioration of the patients' QoL \[[@b21-crt-2015-425]\].

The current study had several limitations. Only women who had engaged in sexual activity within 3 months were included. Propensity score matching was used to make an adjustment for demographic characteristics of the cervical cancer survivors and control group. Inevitable issues, such as selection bias, might exist in this case-control study.

Conclusion
==========

Compared with healthy women, sexual functioning was not impaired in cervical cancer survivors who showed no evidence of disease after primary treatment and engaging in sexual activity. However, in terms of QoL, lymphedema was more problematic in cervical cancer survivors than in the control group. Prospective cohort studies are warranted to confirm these findings.
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###### 

Demographic characteristics of cervical cancer survivors and control group

  Characteristic              Cervical cancer survivor (n=104)   Control group (n=104)   p-value
  --------------------------- ---------------------------------- ----------------------- ---------
  **Age (yr)**                46.95±7.98                         48.86±8.53              0.098
  **Marital status**                                                                     
   Single/Separated/Widowed   14 (13.5)                          11 (10.6)               0.670
   Married                    90 (86.5)                          93 (89.4)               
  **Education (yr)**                                                                     
   ≤ 9                        12 (11.5)                          14 (13.5)               0.834
   \> 9                       92 (88.5)                          90 (86.5)               
  **Family income (\$/mo)**                                                              
   ≤ 2,000                    13 (12.5)                          16 (15.4)               0.833
   \> 2,000 to ≤ 4,000        45 (43.3)                          44 (42.3)               
   \> 4,000                   46 (44.2)                          44 (42.3)               
  **Occupational status**                                                                
   Yes                        45 (43.3)                          49 (47.1)               0.676
   No                         59 (56.7)                          55 (52.9)               
  **Menopause status**                                                                   
   Yes                        76 (73.1)                          67 (64.4)               0.231
   No                         28 (26.9)                          37 (35.6)               
  **Regular exercise**                                                                   
   Yes                        50 (48.1)                          45 (43.3)               0.578
   No                         54 (51.9)                          59 (56.7)               

Values are presented as mean±standard deviation or number (%).

###### 

Clinical characteristics of cervical cancer survivors

  Characteristic               Cervical cancer survivor (n=104)
  ---------------------------- ----------------------------------
  **FIGO stage**               
   Ⅰ                           81 (77.9)
   Ⅱ                           18 (17.3)
   Ⅲ                           4 (3.8)
   Ⅳ                           1 (1.0)
  **Histology**                
   Squamous cell carcinoma     81 (77.9)
   Adenocarcinoma              22 (21.2)
   Small cell carcinoma        1 (1.0)
  **Survival period (yr)**     
   ≤ 2                         31 (29.8)
   \> 2 to ≤ 5                 39 (37.5)
   \> 5                        34 (32.7)
  **Type of treatment**        
   Conization only             14 (13.5)
   Simple hysterectomy only    8 (7.7)
   Radical hysterectomy only   43 (41.3)
   Conization+R+C              2 (1.9)
   Simple hysterectomy+C       1 (1.0)
   Simple hysterectomy+R+C     2 (1.9)
   Radical hysterectomy+C      4 (3.8)
   Radical hysterectomy+R      6 (5.8)
   Radical hysterectomy+R+C    13 (12.5)
   Staging surgery only+R      3 (2.9)
   R only                      1 (1.0)
   R+C                         7 (6.7)
  **Type of surgery**          
   Conization                  16 (15.4)
   Simple hysterectomy         11 (10.6)
   Radical hysterectomy        66 (63.5)
   Staging surgery             3 (2.9)
   No surgery                  8 (7.7)
  **Status of ovaries**        
   Ovaries *in situ*           79 (76.0)
   Ovarian transposition       1 (1.0)
   Bilateral oophorectomy      18 (17.3)
   Unilateral oophorectomy     6 (5.8)

Values are presented as number (%). Staging surgery was defined as performance of pelvic lymphadenectomy and para-aortic lymphadenectomy without hysterectomy. FIGO, International Federation of Gynecology and Obstetrics; R, radiotherapy; C, chemotherapy.

###### 

Comparison of quality of life and sexual function between cervical cancer survivors and control group

  Domain                        Cervical cancer survivor (n=104)   Control group (n=104)   p-value
  ----------------------------- ---------------------------------- ----------------------- ---------
  **EORTC QLQ-C30**                                                                        
   Physical functioning         79.3±15.5                          80.6±14.5               0.539
   Role functioning             85.7±19.8                          87.3±17.1               0.533
   Emotional functioning        77.9±20.9                          76.8±21.9               0.706
   Cognitive functioning        77.9±17.6                          78.4±16.9               0.841
   Social functioning           83.2±24.3                          88.1±21.1               0.117
   Fatigue                      35.1±22.7                          39.9±23.9               0.147
   Nausea and vomiting          5.8±13.3                           8.7±16.9                0.173
   Pain                         15.2±19.6                          19.4±21.7               0.147
   Dyspnea                      12.2±20.8                          12.8±19.9               0.820
   Insomnia                     23.4±27.8                          25.3±26.9               0.613
   Appetite loss                11.2±19.5                          10.3±18.0               0.712
   Constipation                 25.0±28.2                          21.8±28.5               0.416
   Diarrhea                     14.7±21.2                          11.9±22.2               0.339
   Financial difficulties       11.2±20.6                          10.3±21.3               0.741
   Global health status         64.5±20.2                          59.9±20.5               0.108
  **EORTC QLQ-CX24**                                                                       
   Body image                   73.1±25.2                          79.6±18.8               0.036
   Symptom experience           12.1±10.1                          10.5±8.9                0.244
   Lymphedema                   20.2±28.0                          12.2±21.8               0.022
   Peripheral neuropathy        22.4±28.4                          17.0±23.2               0.132
   Menopausal symptoms          20.5±27.2                          17.3±23.2               0.362
   Sexual activity              32.1±24.5                          30.1±26.6               0.583
   Sexual enjoyment             40.1±24.3                          37.8±25.9               0.537
   Sexual/Vaginal functioning   80.6±20.6                          85.4±16.8               0.077
   Sexual worry                 26.6±28.0                          22.0±24.9               0.214
  **FSFI**                                                                                 
   Desire                       3.0±1.0                            2.9±1.1                 0.617
   Arousal                      3.5±1.3                            3.2±1.6                 0.232
   Lubrication                  4.1±1.7                            4.0±1.9                 0.696
   Orgasm                       3.9±1.5                            3.7±1.8                 0.356
   Satisfaction                 4.0±0.7                            3.9±1.2                 0.363
   Pain                         4.5±1.7                            4.1±2.0                 0.214
   Total                        23.0±6.6                           21.9±8.2                0.300

Values are presented as mean±standard deviation. EORTC QLQ-C30, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QLQ-CX24, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module; FSFI, Female Sexual Function Index.

###### 

Summary of studies using the Female Sexual Function Index (FSFI) to assess sexuality in cervical cancer

  Study (year)                                           Study period                             Inclusion criteria         Exclusion criteria                                No. of participants                     Age at study   FSFI total score                        Years since diagnosis                                                                        Measurement                                          Result
  ------------------------------------------------------ ---------------------------------------- -------------------------- ------------------------------------------------- --------------------------------------- -------------- --------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------
  Frumovitz et al. (2005) \[[@b14-crt-2015-425]\], USA   NA                                       Stage I                    Combination of surgical and radiation therapies   RH (n=37)                               43.6           25.1                                    7.5                                                                                          FSFI, SF-12, BSI-18, menopause scale, A-DAS, CARES   Radiotherapy deteriorated sexual functioning
  Age \< 55 yr at the treatment                          CCRT                                     Radiotherapy (n=37)        46.9                                              17.1                                    7.0            \-                                      63% of those sexually active before having cancer remained sexually active after treatment                                                        
  Treatment at least 5 yr previously                     Disease recurrence                       Control (n=40)             42.8                                              26.4                                    \-             \-                                      Sexual functioning and QoL did not differ significantly between surgery and control                                                               
  Disease-free state                                     Treated for other malignancies           \-                         \-                                                \-                                      \-             \-                                      \-                                                                                                                                                
  Surgery or radiotherapy                                \-                                       \-                         \-                                                \-                                      \-             \-                                      \-                                                                                                                                                
  Carter et al. (2008) \[[@b13-crt-2015-425]\], USA      Feb 2004-Jan 2008                        Stage I                    NA                                                RT (n=30)                               18-49          NA                                      NA                                                                                           FSFI, FACT-CX, CES-D                                 At the 6-mo follow-up assessment, 70% of the women were sexually active
  Age 18-49 yr                                           \-                                       \-                         \-                                                \-                                      \-             \-                                      Postoperative dyspareunia decreased over time                                                                                                     
  Serati et al. (2009) \[[@b15-crt-2015-425]\], Italy    Jan 2003-Dec 2007                        Stage IB or IIA            Non-sexually active women                         RH (n=38)                               47 (24-71)     17.2                                    NA                                                                                           FSFI                                                 Radical hysterectomy deteriorated sexual functioning
  Received RH                                            Severe mental illness                    Laparoscopy (n=20)         45.0 (24-69)                                      10.8                                    \-             \-                                      Laparoscopic surgery did not show any benefit on sexuality over the abdominal surgery                                                             
  \-                                                     Severe physical handicap                 Laparotomy (n=18)          44.5 (25-68)                                      21.9                                    \-             \-                                      \-                                                                                                                                                
  \-                                                     Pregnant                                 Control (n=35)             45 (24-69)                                        30.7                                    \-             \-                                      \-                                                                                                                                                
  Carter et al. (2010) \[[@b12-crt-2015-425]\], USA      Feb 2004-Jan 2008                        Stage IA1-IB2              NA                                                RT (n=33)                               32.6           Baseline vs. after 2 yr 17.4 vs. 21.9   NA                                                                                           FSFI, FACT-CX, CES-D, IES                            Sexual functioning and QoL did not differ significantly by surgical type
  Age 18-45 yr                                           \-                                       RH (n=19)                  37.6                                              Baseline vs. after 2 yr 15.7 vs. 22.6   \-             \-                                      \-                                                                                                                                                
  Tsai et al. (2011) \[[@b17-crt-2015-425]\], Taiwan     NA                                       CIS or above age ≥ 20 yr   NA                                                CC (n=105)                              54.3 (28-78)   NA                                      NA                                                                                           FSFI                                                 Older age (Cl, 1.07-1.25)
  Sexual activity 3 yr before the diagnosis              \-                                       \-                         \-                                                \-                                      \-             \-                                      Level of education (≤ 9th grade) (CI, 1.51-10.37)                                                                                                 
  Song et al. (2012) \[[@b16-crt-2015-425]\], Korea      Aug 2010-Nov 2010                        Stage IA-IB1               Refuse to participate in the survey               Conization (n=39)                       34.7           30.7                                    2.5                                                                                          FSFI                                                 Radical trachelectomy and hysterectomy deteriorated sexual function than conization
  Age \< 40 yr                                           Laparotomic approach                     RT (n=18)                  34.7                                              21.7                                    2.5            \-                                      \-                                                                                                                                                
  Sexual activity preoperative                           Oophorectomy with radical surgery        RH (n=24)                  36.8                                              22.4                                    2.3            \-                                      \-                                                                                                                                                
  \-                                                     Adjuvant radiation and/or chemotherapy   \-                         \-                                                \-                                      \-             \-                                      \-                                                                                                                                                
  \-                                                     Disease recurrence                       \-                         \-                                                \-                                      \-             \-                                      \-                                                                                                                                                
  Lee et al., Korea                                      Feb 2013-Jan 2014                        Stage I-IV                 Refuse to participate in the survey               CC (n=104)                              47.0 (24-70)   23.0                                    3.7                                                                                          FSFI, EORTC QLQ-C30, EORTC QLQ-CX24                  Body image and lymphedema were more problematic in cervical cancer survivors
  Age ≥ 18 yr                                            \-                                       Control (n=104)            48.9 (24-66)                                      21.9                                    \-             \-                                      Sexual functioning was not impaired                                                                                                               
  Sexual activity within 3 mo                            \-                                       \-                         \-                                                \-                                      \-             \-                                      \-                                                                                                                                                
  Disease-free state                                     \-                                       \-                         \-                                                \-                                      \-             \-                                      \-                                                                                                                                                

NA, not available; RH, radical hysterectomy; SF-12, Short Form 12; BSI, Brief Symptom Index-18; A-DAS, Abbreviated Dyadic Adjustment Scale; CARES, Cancer Rehabilitation Evaluation System; CCRT, concurrent chemoradiotherapy; QoL, quality of life; RT, radical trachelectomy; FACT, Functional Assessment of Cancer Therapy; CES-D, Center for Epidemiology Studies Depression; IES, Impact of Event Scale; CIS, carcinoma *in situ*; CC, cervical cancer; CI, confidence interval; EORTC QLQ-C30, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QLQ-CX24, EORTC QLQ-Cervical Cancer Module.
